BioMarin Pharmaceutical Inc. (BIT:1BMRN)
Italy · Delayed Price · Currency is EUR 49.40
+1.90 (4.00%)
At close: Jul 11, 2025, 5:30 PM CET
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
NAGLAZYME | 479.58M | Log In | Log In | Log In | Log In | Upgrade |
NAGLAZYME Growth | 21.18% | Log In | Log In | Log In | Log In | Upgrade |
ALDURAZYME | 183.89M | Log In | Log In | Log In | Log In | Upgrade |
ALDURAZYME Growth | 49.58% | Log In | Log In | Log In | Log In | Upgrade |
KUVAN | 120.90M | Log In | Log In | Log In | Log In | Upgrade |
KUVAN Growth | -33.74% | Log In | Log In | Log In | Log In | Upgrade |
FIRDAPSE | - | Log In | Log In | Log In | Log In | Upgrade |
FIRDAPSE Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Royalty and Other | 44.47M | Log In | Log In | Log In | Log In | Upgrade |
Royalty and Other Growth | -7.89% | Log In | Log In | Log In | Log In | Upgrade |
VIMIZIM | 739.78M | Log In | Log In | Log In | Log In | Upgrade |
VIMIZIM Growth | 4.43% | Log In | Log In | Log In | Log In | Upgrade |
BRINEURA | 169.08M | Log In | Log In | Log In | Log In | Upgrade |
BRINEURA Growth | 5.32% | Log In | Log In | Log In | Log In | Upgrade |
PALYNZIQ | 355.05M | Log In | Log In | Log In | Log In | Upgrade |
PALYNZIQ Growth | 17.44% | Log In | Log In | Log In | Log In | Upgrade |
VOXZOGO | 735.09M | Log In | Log In | Log In | Log In | Upgrade |
VOXZOGO Growth | 48.80% | Log In | Log In | Log In | Log In | Upgrade |
ROCTAVIAN | 26.07M | Log In | Log In | Log In | Log In | Upgrade |
Royalty and Other | 44.47M | Log In | Log In | Log In | Log In | Upgrade |
Royalty and Other Growth | -7.89% | Log In | Log In | Log In | Log In | Upgrade |
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
Royalty and Other | 44.47M | Log In | Log In | Log In | Log In | Upgrade |
Royalty and Other Growth | -7.89% | Log In | Log In | Log In | Log In | Upgrade |
Royalty and Other | 44.47M | Log In | Log In | Log In | Log In | Upgrade |
Royalty and Other Growth | -7.89% | Log In | Log In | Log In | Log In | Upgrade |
United States | 924.81M | Log In | Log In | Log In | Log In | Upgrade |
United States Growth | 22.07% | Log In | Log In | Log In | Log In | Upgrade |
Europe | 829.03M | Log In | Log In | Log In | Log In | Upgrade |
Europe Growth | 22.50% | Log In | Log In | Log In | Log In | Upgrade |
Latin America | 378.08M | Log In | Log In | Log In | Log In | Upgrade |
Latin America Growth | 12.96% | Log In | Log In | Log In | Log In | Upgrade |
Rest of World Revenue (Pre-Q3 2024) | - | Log In | Log In | Log In | Log In | Upgrade |
Rest of World Revenue (Pre-Q3 2024) Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other | 677.52M | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | 57.70% | Log In | Log In | Log In | Log In | Upgrade |